Novartis Eyes Broader Market As Pluvicto Hits Mark In Pivotal Second-Line mCRPC Trial
Peak Sales Estimates Could Increase
Executive Summary
The major’s radioligand therapy has succeeded in an earlier line of prostate cancer therapy that presents a large market opportunity, but some observers are keen to see full data before raising their sales projections.
You may also be interested in...
Novartis Culls Pipeline As ‘Pure-Play’ Drive Progresses
The Swiss company has raised its 2023 forecast thanks to stronger Q1 sales, but its transformation towards a more ‘pure-play’ pharma company is still a work in progress.
Weak Spots Blight Novartis Third Quarter As New Products Shine
A mixed sales bag for the Swiss major in Q3 saw a strong start for Pluvicto dampened by a reverse for Zolgensma, weak growth for Cosentyx and continued sluggishness for Leqvio. Positive data for potential blockbuster iptacopan were another bright spot, as Novartis prioritizes the delivery of high value medicines, and concentrates on the US market.
Keeping Track: Pluvicto Boosts Novartis In Radiotherapy; BMS Builds Out IO Estate With Opdualag
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.